New 52 Week Low Today

Revance Therapeutics Inc RVNC:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 12:17 PM EDT
2.79quote price arrow down-0.13 (-4.49%)
Volume
1,290,978
52 week range
2.73 - 33.10
Loading...
  • Open2.95
  • Day High2.96
  • Day Low2.73
  • Prev Close2.92
  • 52 Week High33.10
  • 52 Week High Date05/23/23
  • 52 Week Low2.73
  • 52 Week Low Date05/23/24

Key Stats

  • Market Cap291.296M
  • Shares Out104.45M
  • 10 Day Average Volume2.98M
  • Dividend-
  • Dividend Yield-
  • Beta1.04
  • YTD % Change-67.86

KEY STATS

  • Open2.95
  • Day High2.96
  • Day Low2.73
  • Prev Close2.92
  • 52 Week High33.10
  • 52 Week High Date05/23/23
  • 52 Week Low2.73
  • 52 Week Low Date05/23/24
  • Market Cap291.296M
  • Shares Out104.45M
  • 10 Day Average Volume2.98M
  • Dividend-
  • Dividend Yield-
  • Beta1.04
  • YTD % Change-67.86

RATIOS/PROFITABILITY

  • EPS (TTM)-3.61
  • P/E (TTM)-0.77
  • Fwd P/E (NTM)-1.20
  • EBITDA (TTM)-201.002M
  • ROE (TTM)-2,096.78%
  • Revenue (TTM)236.645M
  • Gross Margin (TTM)69.11%
  • Net Margin (TTM)-132.57%
  • Debt To Equity (MRQ)-435.62%

EVENTS

  • Earnings Date08/05/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Revance Therapeutics Inc

 

Profile

MORE
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar...
Angus Russell
Independent Chairman of the Board
Mark Foley
Chief Executive Officer, Director
Tobin Schilke
Chief Financial Officer
Address
1222 Demonbreun Street, Suite 2000
Nashville, TN
37203
United States

Top Peers

SYMBOLLASTCHG%CHG
ME
23andMe Holding Co.
0.5205-0.0028-0.5351%
PBYI
Puma Biotechnology Inc
4.14-0.09-2.13%
AKBA
Akebia Therapeutics Inc
1.10UNCHUNCH
XERS
Xeris Biopharma Holdings Inc
2.00-0.01-0.75%
CHRS
Coherus BioSciences Inc
2.06-0.05-2.37%